Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor
Authors
Keywords
-
Journal
HISTOPATHOLOGY
Volume 67, Issue 6, Pages 799-805
Publisher
Wiley
Online
2015-04-03
DOI
10.1111/his.12709
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
- (2015) Anna S. Berghoff et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices
- (2014) Eric Jonasch et al. CURRENT MEDICAL RESEARCH AND OPINION
- Amplification and overexpression ofCMETis a common event in brain metastases of non-small cell lung cancer
- (2014) Matthias Preusser et al. HISTOPATHOLOGY
- Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
- (2014) Grzegorz J. Korpanty et al. Frontiers in Oncology
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
- (2013) Roger B. Cohen CANCER TREATMENT REVIEWS
- Prognostic significance and targeting of HER family in colorectal cancer
- (2013) Helmout Modjtahedi Frontiers in Bioscience-Landmark
- Prolonged Survival of a Patient With Papillary Renal Cell Carcinoma and Brain Metastases Using Pazopanib
- (2013) Corbin Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- Outcome of Patients With Renal Cell Carcinoma Metastatic to the Brain Treated With Sunitinib Without Local Therapy
- (2012) Zita Dubauskas Lim et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma
- (2012) Jonathan Verma et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients
- (2012) William R Sukov et al. MODERN PATHOLOGY
- Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma
- (2011) Sarah Minner et al. CANCER
- Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma
- (2011) Jonathan Verma et al. CANCER
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
- (2010) Elisa Benedettini et al. AMERICAN JOURNAL OF PATHOLOGY
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search